- Home
- ABEO vs EU Comparison
ABEO vs EU Comparison
Compare ABEO & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | EU |
|---|---|---|
| Founded | 1974 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.5M | 361.2M |
| IPO Year | 2005 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ABEO | EU |
|---|---|---|
| Price | $5.49 | $1.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $20.00 | $4.00 |
| AVG Volume (30 Days) | 1.0M | ★ 2.6M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | 11.76 |
| EPS | N/A | N/A |
| Revenue | $2,998,000.00 | ★ $43,155,000.00 |
| Revenue This Year | $1,024.31 | $212.11 |
| Revenue Next Year | $145.42 | $29.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $1.54 |
| 52 Week High | $7.54 | $4.19 |
Technical Indicators
Market Signals| Indicator | ABEO | EU |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 31.76 |
| Support Level | $5.24 | N/A |
| Resistance Level | $5.54 | $2.83 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 35.50 | 1.09 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.